Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(Harvard University), Beverly Moy(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Seth A. Wander(Massachusetts General Hospital), Neelima Vidula(Harvard University), Phoebe Ryan(Harvard University), Leif W. Ellisen(Harvard University), Geoffrey Fell(Harvard University), Elizabeth Abraham(Harvard University), Steven J. Isakoff(Harvard University), Jennifer Shin(Massachusetts General Hospital), Arielle J. Medford(Harvard University)
Cited by 53
Related Papers
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846